diabetes tirzepatide Improved Weight, Control in Patients With HIV FDA approves tirzepatide, Eli Lilly's

On the other hand, obesity is also characterized with increased UA levels

Metabolism (1997) 46:12704

Metabolic profiling stratifies colorectal cancer and reveals adenosylhomocysteinase as a therapeutic target

Initially developed as a treatment for type 2 diabetes, the drug gained widespread attention after clinical trials showed it reduced baseline body weight by approximately 10%-15%

While standard therapeutic doses have demonstrated cardiovascular and metabolic benefits in large clinical trials, the concept of using low dose GLP-1 for inflammation remains investigational, with no established FDA indication or standardized dosing protocols